FNArena Windows

Introduction to FNArena Windows

FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.

Latest Stories

Sleep apnoea revenue partly offset weaker software-as-a-service revenue in the March quarter for ResMed, which is gaining share from the strong uptake of new products.

May 06 2019

Cochlear has launched its MRI-compatible implant but brokers do not expect the new product will impact revenue and market share until FY20.

Apr 17 2019


ASX CODE LAST PRICE % MOVE 52WK HIGH 52WK LOW P/E CONSENSUS TARGET UPSIDE/DOWNSIDE
COH $203.00

1.86%

$221.44 $155.22 43.0

$170.30

-16.1%

FPH $15.56

0.71%

$15.57 $11.28 45.4

IDX $3.11

0.32%

$3.30 $2.35 19.0

$3.207

3.1%

IPD $0.20 0.00% $0.56 $0.18

$0.79

295.0%

MX1 $0.28 0.00% $0.42 $0.20

$0.50

78.6%

NAN $4.57

0.44%

$5.02 $2.55 152.0

$4.55

-0.4%

ONE $0.25 0.00% $2.08 $0.23

$0.98

292.0%

PME $21.32

1.67%

$21.96 $7.01 133.3

$23.69

11.1%

RAP $0.14 0.00% $0.28 $0.07

$0.23

64.3%

RMD $16.42

0.74%

$16.57 $12.65 32.8

$16.448

0.2%

SOM $1.80 0.00% $2.48 $1.46

$2.17

20.6%

VHT $1.84

0.55%

$1.95 $0.71

$1.78

-3.3%

Previous Stories
RESEARCH: Anteo Diagnostics, Nano-chemistry Tech Developer

Mar 20 2019

Pitt Street Research initiates coverage of Anteo Diagnostics, Brisbane-based nanochemistry technology and diagnostics company.


Is Cochlear Too Expensive?

Feb 20 2019

Cochlear’s services and upgrade business is expected to feature over the rest of the year, until the company reasserts its leadership in product innovation and new implant growth gets back on track.


ResMed To Stall

Feb 05 2019

Michael Gable of Fairmont Equities suggest that after its big sell-off, ResMed is most likely to stall for a period before recovering.


Nanosonics On The Move

Jan 30 2019

Michael Gable of Fairmont Equities suggests Nanosonics has broken to the upside following a pullback.


ResMed Judged Harshly As Costs Mount

Jan 30 2019

The core sleep therapy business of ResMed remains solid but brokers and the market have judged the stock harshly as details emerge regarding the cost of acquisitions.


ResMed Propels Forward

Dec 06 2018

ResMed will acquire Propeller Health, which provides connected care for patients with COPD and asthma. Brokers believe the acquisition puts ResMed at the forefront of this market.


Is F&P Healthcare Overvalued?

Nov 27 2018

Brokers consider Fisher & Paykel Healthcare is overvalued, as litigation and competitive headwinds buffet the business.


ResMed Expands Presence In Home Health

Nov 07 2018

The price ResMed is paying for MatrixCare is rich, although brokers accept the deal will significantly expand its offering in home health data analytics.


ResMed Increases Market Dominance

Oct 29 2018

ResMed has impressed with solid revenue growth across all divisions in the September quarter, while an expanding digital platform is driving re-supply and improving adherence to the company’s products.


Nanosonics: Buy The Dips

Oct 02 2018

Michael Gable of Fairmont Equities suggests Nanosonics has broken outof its period of pullback.